Your Yourlocation: Home > Tiotropium bromide(136310-93-5) / Olodaterol compound for chronic obstructive pulmonary disease

Boehringer Ingelheim has submitted to the European Medicines Agency (EMA) the listing of its respiratory compound drug application. The EMA will now decide whether to evaluate this tiotropium bromide(136310-93-5) / Olodaterol compound for chronic obstructive pulmonary disease (COPD) based on data provided by Boehringer Ingelheim.

The combination of Boehringer Ingelheim's top-selling drug tiotropium bromide(136310-93-5) and the company's other respiratory therapies Striverdi (Olodaterol). Tiotropium is the world's best-selling drug list of drugs, its 2013 sales of about 5 billion US dollars.

However, this drug will soon lose patent protection, Boehringer Ingelheim is studying how to extend its franchise life. Striverdi has not yet reached the same height as tiotropium, which was approved earlier this year.

Boehringer Ingelheim has pinned its hopes on this potential combination therapy, tiotropium bromide(136310-93-5) is a maintenance treatment of COPD drugs, and Striverdi is a one-day use, rapid long-acting beta receptor agonist (LABA ). "The combination of tiotropium and Olodaterol fixed dose represents a significant step forward in our strong breath product portfolio," said Dr. Dugi, chief medical officer of Boehringer Ingelheim.

"Millions of patients with COPD have been destroyed by the disease and, once approved, we believe it will make a significant contribution to addressing this unmet medical need."

Boehringer Ingelheim has reported positive late-phase data from the combination, which proved to be more effective in improving lung function after 6 weeks of treatment than any single drug in placebo or combination therapy. Other COPD compounds consist of drugs approved or under development, including drugs from GlaxoSmithKline and Novartis.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved